



Supplementary Materials

Rivastigmine–Benzimidazole Hybrids as Promising Multitarget Metal-Modulating Compounds for Potential Treatment of Neurodegenerative Diseases

David Vicente-Zurdo ^{1,2}, Leonardo Brunetti ^{1,3}, Luca Piemontese ³, Beatriz Guedes ⁴, Sandra M. Cardoso ^{4,5}, Daniel Chavarria ⁶, Fernanda Borges ⁶, Yolanda Madrid ², Sílvia Chaves ^{1,*} and M. Amélia Santos ^{1,*}

¹ Centro de Química Estrutural, Departamento de Engenharia Química, Institute of Molecular Sciences, Instituto Superior Técnico, Universidade de Lisboa, Av. Rovisco Pais 1, 1049-001 Lisboa, Portugal

² Department of Analytical Chemistry, Faculty of Chemistry, Complutense University of Madrid, Avenida Complutense s/n, 28040 Madrid, Spain

³ Department of Pharmacy—Pharmaceutical Sciences, University of Bari Aldo Moro, via E. Orabona 4, 70125 Bari, Italy

⁴ CNC—Center for Neuroscience and Cell Biology, University of Coimbra, 3000-370 Coimbra, Portugal

⁵ FMUC—Faculty of Medicine, University of Coimbra, 3000-370 Coimbra, Portugal

⁶ CIQUP-IMS, Department of Chemistry and Biochemistry, Faculty of Sciences, University of Porto, Rua do Campo Alegre s/n, 4169-007 Porto, Portugal

* Correspondence: silvia.chaves@tecnico.ulisboa.pt (S.C.); masantos@tecnico.ulisboa.pt (M.A.S.)




Figure S1. Absorption spectra for the Fe(III)/**5a** 1:3 system ($2.71 < \text{pH} < 5.91$) in 50% (w/w) DMSO/H₂O ($C_L = 4 \times 10^{-5}$ M) and outset with individual calculated spectra by Psequad.




Figure S2. Docking results for RIV-BIM hybrids: (a) **5a** (yellow) with *h*-MAOA (PDB code: 2BXR) and (b) **4a** (pink) with *h*-MAOB (PDB code: 2V5Z). Pose comparisons with original ligand (green).